Grootes Isabelle, Wishart Gordon C, Pharoah Paul David Peter
Department of Oncology, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
School of Medicine, Anglia Ruskin University, Cambridge, UK.
NPJ Breast Cancer. 2024 Jan 15;10(1):6. doi: 10.1038/s41523-024-00612-y.
PREDICT Breast ( www.breast .predict.nhs.uk ) is a prognostication tool for early invasive breast cancer. The current version was based on cases diagnosed in 1999-2003 and did not incorporate the benefits of radiotherapy or the harms associated with therapy. Since then, there has been a substantial improvement in the outcomes for breast cancer cases. The aim of this study was to update PREDICT Breast to ensure that the underlying model is appropriate for contemporary patients. Data from the England National Cancer Registration and Advisory Service for invasive breast cancer cases diagnosed 2000-17 were used for model development and validation. Model development was based on 35,474 cases diagnosed and registered by the Eastern Cancer Registry. A Cox model was used to estimate the prognostic effects of the year of diagnosis, age at diagnosis, tumour size, tumour grade and number of positive nodes. Separate models were developed for ER-positive and ER-negative disease. Data on 32,408 cases from the West Midlands Cancer Registry and 100,551 cases from other cancer registries were used for validation. The new model was well-calibrated; predicted breast cancer deaths at 5-, 10- and 15-year were within 10 per cent of the observed validation data. Discrimination was also good: The AUC for 15-year breast cancer survival was 0.809 in the West Midlands data set and 0.846 in the data set for the other registries. The new PREDICT Breast model outperformed the current model and will be implemented in the online tool which should lead to more accurate absolute treatment benefit predictions for individual patients.
PREDICT Breast(www.breast.predict.nhs.uk)是一种用于早期浸润性乳腺癌的预后评估工具。当前版本基于1999年至2003年诊断的病例,未纳入放疗的益处或治疗相关的危害。从那时起,乳腺癌病例的治疗结果有了显著改善。本研究的目的是更新PREDICT Breast,以确保基础模型适用于当代患者。使用来自英格兰国家癌症登记与咨询服务中心的2000年至2017年诊断的浸润性乳腺癌病例数据进行模型开发和验证。模型开发基于东部癌症登记处诊断并登记的35474例病例。使用Cox模型估计诊断年份、诊断时年龄、肿瘤大小、肿瘤分级和阳性淋巴结数量的预后影响。分别为雌激素受体(ER)阳性和ER阴性疾病开发了模型。使用西米德兰兹癌症登记处的32408例病例数据和其他癌症登记处的100551例病例数据进行验证。新模型校准良好;预测的5年、10年和15年乳腺癌死亡人数在观察到的验证数据的10%以内。区分能力也很好:在西米德兰兹数据集中,15年乳腺癌生存率的曲线下面积(AUC)为0.809,在其他登记处的数据集中为0.846。新的PREDICT Breast模型优于当前模型,并将在在线工具中实施,这将为个体患者带来更准确的绝对治疗获益预测。